In this episode, we dive into the hottest updates in myeloma and amyloidosis at ASH 2024 annual meeting with Dr. Rakesh Popat. Here are the abstracts we discussed:
1. AQUILA Trial in High-Risk SMM
- Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring.
- Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara.
- Insights into modes of progression, adequacy of active surveillance, and post-protocol therapy in control arm.
- Read the abstract.
- Read the simultaneous publication at NEJM.
2. Anito-Cel: New BCMA CAR T Therapy
- Early data from the iMMagine-1 trial showing strong efficacy and a promising safety profile for Anito-Cel, a novel BCMA CAR T.
- Discussion of its potential to rival cilta-cel while avoiding neurotoxicity concerns.
- Read the abstract.
3. CARTITUDE-4 Update
- Updates on MRD-negativity rates and survival outcomes for cilta-cel in relapsed myeloma, with significant benefits over standard care.
- Read the abstract.
4. ANDROMEDA OS Data in AL Amyloidosis
- Long-term data showing an overall survival (OS) benefit of Dara-VCd over VCd in AL amyloidosis.
- Insights into cardiac responses and crossover impact.
- Read the abstract.
5. OPTIMUM Trial in Ultra-High-Risk NDMM
- Five-year follow-up of a tailored approach for ultra-high-risk newly diagnosed myeloma patients with continuous therapy incorporating multiple active agents.
- Subgroup outcomes highlighting both challenges and exceptional results.
- Read the abstract
6. GMMG-HD7 Trial PFS Update
7. Exciting New Drugs
- Review of three innovative therapies: inobrodib, a BCMA-CD38 trispecific antibody, and cevostamab, a FcRH5-targeted bispecific antibody.
- Expert insights into their efficacy and potential to reshape myeloma care.
- Read the abstract
